Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innovex, the commercialization division of Quintiles Transnational, has secured a deal to promote Advancis Pharmaceutical's recently approved 333mg and 750mg strengths of its cephalosporin antibiotic, Keflex capsules.
Subscribe to our email newsletter
Under the two-year agreement, Innovex will provide contract sales, marketing, and commercialization services, including sales representative recruitment, sales force automation and sample accountability services, promotional education programs and other related commercialization services.
“We are very pleased to have Innovex as a key Advancis partner and to have their significant experience and sales expertise dedicated to the launch and commercial success of our new Keflex strengths,” said Dr Edward Rudnic, president and CEO of Advancis.
Advancis acquired the rights to manufacture, market, and sell Keflex in the US in July of 2004. Cephalexin, the active ingredient of Keflex, is the third most prescribed outpatient antibiotic in the US, with more than 25 million prescriptions written annually.